Sentynl Takes U.S. Option on Mereo’s Alvelestat

Company: Mereo BioPharma · Event Type: Deal and Financing · Product/Asset: alvelestat · Subject: Alpha-1 Antitrypsin Deficiency · Event Date: August 11, 2026 Summary Sentynl Therapeutics and Mereo BioPharma entered an option and license agreement for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease. Sentynl receives…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal